Diverticulosis is an often-asymptomatic GI condition affecting large populations. Diverticulosis often progresses to a more serious GI disease - diverticulitis - a debilitating disease that typically requires surgical intervention. Limited clinical observations have shown that Endari may be effective in treating diverticulosis by slowing or stopping the progression of the disease to diverticulitis. Emmaus has begun a small pilot trial in the first half of 2019 to study the potential use of l-glutamine as a new treatment for patients with diverticulosis.